Peptide News: Retatrutide Goes to the Seventh Circuit, and How to Vet a Telehealth Provider

Tomorrow, a federal appeals court hears the case that decides whether retatrutide, Eli Lilly’s next-generation obesity drug, is legally a “drug” or a “biologic.” That label settles whether any version of it could ever be compounded. The same week is a good moment to look at the other side of peptide access: telehealth. The FDA has spent 2026 cracking down on online providers that blur what they’re actually selling. Here’s what to watch in court, and how to tell a trustworthy telehealth provider from a risky one.

Retatrutide Goes Before the Seventh Circuit on September 24

The case, Eli Lilly and Company v. Robert F. Kennedy, Jr., is scheduled for oral argument before the U.S. Court of Appeals for the Seventh Circuit on September 24, 2026.

The dispute is about counting. Under the FDA’s bright-line rule, a molecule is a “protein,” and so a biologic, only if it has more than 40 amino acids in a single chain. Retatrutide’s backbone has 39. Lilly points out that a two-amino-acid side chain bonded to that backbone brings the total to 41. The agency says only the main chain counts.

On September 30, 2025, Judge Tanya Walton Pratt of the Southern District of Indiana found the FDA had acted arbitrarily and vacated its classification. She stopped short of declaring retatrutide a biologic and sent the question back to the agency. Lilly appealed in February 2026, asking the Seventh Circuit to order biologic status outright.

Why the label matters to patients, not just lawyers

Exclusivity: a biologic gets 12 years of market exclusivity, compared with 5 for a conventional drug. That’s worth billions to Lilly.
Compounding: federal law excludes biologics from the compounding exemptions that let pharmacies prepare copies of drugs during shortages. If retatrutide is a biologic, no pharmacy could ever legally compound it.
Timing: Lilly has said it’s targeting a submission to the FDA in the first quarter of 2027, so the classification shapes which approval pathway the drug takes.

The practical takeaway is the same whatever the court decides. Retatrutide is still in Phase 3 trials and isn’t FDA-approved for any use. Any retatrutide sold online today is being sold illegally. Earlier this year, CBP officers at the Port of Cincinnati intercepted roughly 5,000 mislabeled peptide shipments from China in 300 master cartons, including semaglutide, tirzepatide and retatrutide.

The Telehealth Question: What the FDA Has Been Warning About

Telehealth makes physician-guided care far more accessible, and it has also attracted companies that market like retailers. In March 2026 the FDA made public warning letters to 30 telehealth companies over how they marketed compounded GLP-1 weight-loss drugs. The agency flagged claims that:

suggested compounded products were identical to FDA-approved brands,
obscured where medications actually came from, and
put the telehealth company’s own brand on a drug in ways that implied it was the compounder.

“It’s a new era,” FDA Commissioner Marty Makary said, adding that the agency is “taking swift action” on misleading claims across all media platforms. Trade press reported that the FDA has sent more warning letters in the past six months than in the previous decade combined.

The quality concern is real too. Novo Nordisk has reported that its testing of some compounded semaglutide products found impurity levels as high as 86%. That’s one manufacturer’s testing, but it echoes the three Texas compounding recalls we covered last week.

How to Vet a Telehealth Peptide Provider

Before you sign up anywhere, including with us, you should be able to answer yes to each of these:

Is a licensed physician in your state actually reviewing your history? A questionnaire that ends at a checkout page isn’t a consultation.
Can they name the dispensing pharmacy, and is it licensed and accredited? You should know who makes what you take.
Do they avoid “same as the brand” or “FDA-approved” language for compounded products? Compounded medications aren’t FDA-approved, and honest providers say so.
Will they tell you no? A provider that only prescribes what’s clinically appropriate, and legally dispensable today, will sometimes decline.

Where the Compounding Review Stands

No change this week. The FDA advisory committee’s July recommendation to add BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon to the 503A Bulks List is still awaiting HHS action, followed by notice-and-comment rulemaking. Legal analysts have estimated the full process typically takes eight to twelve months before pharmacies have clear authority to compound.

Why This Matters If You’re Considering Peptide Therapy

Physician-guided only. Every treatment plan is reviewed and prescribed by an independent physician licensed in your state, and only when clinically appropriate.
Vetted, licensed U.S. pharmacies. We work with licensed U.S. pharmacy partners held to accreditation-level standards, not just a baseline license.
Care that adapts as the rules change. Whatever the Seventh Circuit decides, your plan follows what can be legally and safely dispensed.

FAQ

What is the Seventh Circuit deciding about retatrutide?

Whether the FDA must treat retatrutide as a biologic. The FDA’s rule requires more than 40 amino acids in one chain; retatrutide’s backbone has 39 plus a two-amino-acid side chain. Oral argument is September 24, 2026.

Could retatrutide ever be compounded?

Not if it’s classified as a biologic, because biologics are excluded from compounding exemptions. It’s also not FDA-approved today, so any retatrutide sold now is being sold illegally.

Are compounded GLP-1s the same as Wegovy or Zepbound?

No. Compounded drugs aren’t FDA-approved, and the FDA has warned telehealth companies against implying they’re identical to branded products.

How can I tell if a telehealth provider is legitimate?

Look for a licensed physician in your state reviewing your history, a named and licensed dispensing pharmacy, honest labeling of compounded products, and a provider willing to say no when a therapy isn’t appropriate.

This article is for informational purposes only and does not constitute medical advice. Peptide therapy should only be pursued under the guidance of a licensed physician.

Retatrutide Goes to the Seventh Circuit, and How to Vet a Telehealth Provider